PEB - Pacific Edge Ltd

[LEMON]

6 executive team members hired in the past 6 months, all focused on growth. Even if this Ann today isn't great they are hiring by meeting demand at this time or PEB is preparing for what's going to be an accelerated reach in growth this coming months. Either way, the direction of the SP goes today I will hold and if it drops I will be topping up. Good luck all

[calledone]

6 executive team members hired in the past 6 months, all focused on growth. Even if this Ann today isn't great they are hiring by meeting demand at this time or PEB is preparing for what's going to be an accelerated reach in growth this coming months. Either way, the direction of the SP goes today I will hold and if it drops I will be topping up. Good luck all

Agree with you. I’m topping up both ways up or down(provide numbers from KP shows some traction) but will top up much more if SP goes up.

[silu]

Highlights:
FLLYR: PEB: PEB Financial Results for the 12 months to 31 March 2021

PACIFIC EDGE FINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2021
Pacific Edge reports strong growth momentum despite COVID-19

Summary of performance for the period (% changes compared to prior
comparative period (pcp)):

o Total revenue increased 101% to $10.4m, with operating revenue from test
sales up 76% to $7.7m, despite the negative impact from COVID-19 on test
volumes
o Cash receipts from customers increased 52% on pcp to $6.7m
o Total operating expenses increased 2% on pcp to $24.7m
o Net Loss After Tax improved 25% to $(14.2)m
o Net cash, cash equivalents and short-term deposits increased 56% to $23.1m
as at 31 March 2021
o Operating revenue and cash receipts benefited from reimbursement coverage
by Centers for Medicare and Medicaid Services (CMS) for Cxbladder Detect and
Cxbladder Monitor from 1 July 2020
o Strong performance in 2H21 driven by CMS reimbursement coverage from 1 July
2020 and growing commercial adoption of Cxbladder following a significant
negative impact on test volumes from COVID-19 pandemic in 1H21
o Commercial test use by Kaiser Permanente commenced in late 2020 at a slower
rate than initially expected due to COVID-19 challenges and demands on
physicians; demand is now starting to lift as restrictions ease
o Positive results from the scale-up of US commercial operations starting to
be seen in late Q4 FY21 with record test volumes and U.S. cash receipts
recorded in March 2021
o Positive growth outlook with opportunities being deployed in all target
markets, particularly the U.S.
o Increasing test volumes expected to underpin strong revenue and operating
cashflow growth in FY22 and beyond

[850man]

Summary of performance for the period (% changes compared to prior comparative period (pcp)):
• Total revenue increased 101% to $10.4m, with operating revenue from test sales up 76% to $7.7m, despite the negative impact from COVID-19 on test volumes
• Cash receipts from customers increased 52% on pcp to $6.7m
• Total operating expenses increased 2% on pcp to $24.7m
• Net Loss After Tax improved 25% to $(14.2)m
• Net cash, cash equivalents and short-term deposits increased 56% to $23.1m as at 31 March 2021
• Operating revenue and cash receipts benefited from reimbursement coverage by Centers for Medicare and Medicaid Services (CMS) for Cxbladder Detect and Cxbladder Monitor from 1 July 2020
• Strong performance in 2H21 driven by CMS reimbursement coverage from 1 July 2020 and growing commercial adoption of Cxbladder following a significant negative impact on test volumes from COVID-19 pandemic in 1H21
• Commercial test use by Kaiser Permanente commenced in late 2020 at a slower rate than initially expected due to COVID-19 challenges and demands on physicians; demand is now starting to lift as restrictions ease
• Positive results from the scale-up of US commercial operations starting to be seen in late Q4 FY21 with record test volumes and U.S. cash receipts recorded in March 2021
• Positive growth outlook with opportunities being deployed in all target markets, particularly the U.S.
• Increasing test volumes expected to underpin strong revenue and operating cashflow growth in FY22 and beyond

[Roskat]

Is todays report available to view live today? Cheers

[t.rexjr]

Test throughput is the same so revenue uplift is literally because they are now being paid for the tests... Though no doubt there is definitely a rather large momentum shift in play

[winner69]

Some 25% of the 10m revenue from grants and covid support ....that’s good

Cash burn pretty hefty


But things going to plan ....great future.

[zs_cecil]

Pay attention to Note 5 from the financial statements. It provides very useful insight of the revenue regonition and source. It also provide some info about 'medically necessary' and 'Medicare Adcantage'.

[tomm]

Dub dubs.....

[tomm]

The potentials of this business are so high, all the gears are in places, now just.. VROOM...VROOM...VROOM...
This business is a gold mine to invest for the future.